LT3840837T - Arginazės inhibitoriai ir jų panaudojimo būdai - Google Patents

Arginazės inhibitoriai ir jų panaudojimo būdai

Info

Publication number
LT3840837T
LT3840837T LTEPPCT/EP2019/072341T LTEP2019072341T LT3840837T LT 3840837 T LT3840837 T LT 3840837T LT EP2019072341 T LTEP2019072341 T LT EP2019072341T LT 3840837 T LT3840837 T LT 3840837T
Authority
LT
Lithuania
Prior art keywords
methods
arginase inhibitors
arginase
inhibitors
Prior art date
Application number
LTEPPCT/EP2019/072341T
Other languages
English (en)
Inventor
Dedong Wu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of LT3840837T publication Critical patent/LT3840837T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/22Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEPPCT/EP2019/072341T 2018-08-22 2019-08-21 Arginazės inhibitoriai ir jų panaudojimo būdai LT3840837T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721113P 2018-08-22 2018-08-22
PCT/EP2019/072341 WO2020038983A1 (en) 2018-08-22 2019-08-21 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
LT3840837T true LT3840837T (lt) 2024-06-10

Family

ID=67742403

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2019/072341T LT3840837T (lt) 2018-08-22 2019-08-21 Arginazės inhibitoriai ir jų panaudojimo būdai

Country Status (24)

Country Link
US (1) US11952392B2 (lt)
EP (2) EP3840837B1 (lt)
JP (1) JP7441210B2 (lt)
KR (1) KR102668252B1 (lt)
CN (1) CN112584900A (lt)
AU (1) AU2019323663B2 (lt)
CA (1) CA3109100A1 (lt)
CL (1) CL2021000430A1 (lt)
DK (1) DK3840837T3 (lt)
EA (1) EA202190532A1 (lt)
ES (1) ES2980252T3 (lt)
FI (1) FI3840837T3 (lt)
HR (1) HRP20240694T1 (lt)
HU (1) HUE066903T2 (lt)
IL (1) IL280924B2 (lt)
LT (1) LT3840837T (lt)
MA (1) MA53427A (lt)
MX (1) MX2021002042A (lt)
PL (1) PL3840837T3 (lt)
PT (1) PT3840837T (lt)
RS (1) RS65608B1 (lt)
SG (1) SG11202101618PA (lt)
SI (1) SI3840837T1 (lt)
WO (1) WO2020038983A1 (lt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112384515A (zh) 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション A2a/a2b阻害剤としての縮合ピリミジン誘導体
EP3818063A1 (en) 2018-07-05 2021-05-12 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
MA56324B1 (fr) * 2019-02-08 2023-10-31 Astrazeneca Ab 151 85 Soedertaelje Inhibiteurs de l'arginase et leurs procédés d'utilisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068830B (zh) * 2010-04-22 2016-06-29 马尔斯公司 精氨酸酶抑制剂及其治疗应用
WO2016210106A1 (en) * 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2018089490A1 (en) * 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
PT3559009T (pt) 2016-12-22 2021-05-04 Calithera Biosciences Inc Composições e métodos para inibir a atividade da arginase
WO2019159120A1 (en) 2018-02-17 2019-08-22 Astrazeneca Ab Arginase inhibitors and methods of use thereof
EP3765006A4 (en) 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
CN111770756B (zh) 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
KR102668252B1 (ko) 2024-05-21
EA202190532A1 (ru) 2021-07-08
JP7441210B2 (ja) 2024-02-29
HRP20240694T1 (hr) 2024-08-16
AU2019323663B2 (en) 2022-07-14
CA3109100A1 (en) 2020-02-27
PL3840837T3 (pl) 2024-08-19
PT3840837T (pt) 2024-06-14
IL280924A (en) 2021-04-29
EP4371614A2 (en) 2024-05-22
KR20210049120A (ko) 2021-05-04
IL280924B1 (en) 2024-06-01
ES2980252T3 (es) 2024-09-30
IL280924B2 (en) 2024-10-01
US20210332068A1 (en) 2021-10-28
SG11202101618PA (en) 2021-03-30
RS65608B1 (sr) 2024-07-31
US11952392B2 (en) 2024-04-09
FI3840837T3 (fi) 2024-06-03
HUE066903T2 (hu) 2024-09-28
DK3840837T3 (da) 2024-06-10
CL2021000430A1 (es) 2021-09-03
EP3840837B1 (en) 2024-03-20
CN112584900A (zh) 2021-03-30
WO2020038983A1 (en) 2020-02-27
SI3840837T1 (sl) 2024-07-31
AU2019323663A1 (en) 2021-04-08
MA53427A (fr) 2021-12-01
MX2021002042A (es) 2021-04-28
JP2021535111A (ja) 2021-12-16
EP3840837A1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
IL276711A (en) Arginase inhibitors and methods of using them
EP3700527A4 (en) PAPD5 INHIBITORS AND THEIR METHODS OF USE
IL287940A (en) fgfr inhibitors and methods of using them
IL279475A (en) Actonucleotidase inhibitors and methods of using them
IL287751A (en) kcnt1 inhibitors and methods of use
IL283592A (en) Apol1 inhibitors and methods of using them
IL284640A (en) PCSK9 inhibitors and methods of using them
IL287768A (en) kcnt1 inhibitors and methods of use
IL287973A (en) acss2 inhibitors and methods of their use
EP3765006A4 (en) ARGINASE INHIBITORS AND METHODS OF USE
IL280924A (en) Arginase inhibitors and methods of using them
EP3810615A4 (en) ARGINASE INHIBITORS AND METHODS OF USE
IL284661A (en) pcsk9 inhibitors and methods of using them
IL274504A (en) 2ACSS inhibitors and methods of their use
EP3897622A4 (en) ARGINASE INHIBITORS AND METHODS OF USE
EP3846808A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
IL286149A (en) Caspase inhibitors and methods of using them
EP3793552C0 (en) ABHD12 INHIBITORS AND METHODS OF MANUFACTURE AND USE THEREOF
IL285108A (en) Arginase inhibitors and methods of using them